Jon Weidanz

AbeXXa Biologics, Inc. is engaged in biopharmaceutical services. The company was founded by Jon Weidanz and Debra Weidanz in 2015 and is headquartered in Arlington, TX.

MHC Biologics, LLC, an emerging biotechnology company, has developed a unique and proprietary portfolio of breakthrough technologies that can be used in the development and design of novel therapeutics, including therapeutic vaccines for cancer and other diseases. MHC Biologics has been founded to focus on clinical applications of a suite of immunology tools developed in the laboratories of Dr. Jon Weidanz, Texas Tech University Pharmacy School and Receptor Logic, Ltd., and Dr. William Hildebrand, Oklahoma University Health Science Center and Pure Vaccine Solutions, LLC. These technology 'tools' can be utilized for immunology-based cancer diagnosis and treatment. Funded and managed by life sciences venture firm, Emergent Technologies, Inc., MHC Biologics is actively seeking commercialization partners. MHC Biologics offers breakthrough therapeutic antibody technology targeting a new class of disease biomarkers - peptides presented by the Major Histocompatibility Complex (MHC; also known as human leukocyte antigen, or HLA). These peptides are derived from intracellular processing of tumor or viral proteins and are presented as complexes with MHC proteins on antigen-presenting cells. MHC Biologics' unique antibody strategy exhibits disease-specific binding and efficacy in preclinical studies as a cancer therapeutic modality, providing next-generation products for treatment of cancer and other important diseases.

Part of ImmunityBio, Inc., Sunol Molecular Corp. is a private company that develops gel therapeutics to treat disorders associated with the human tissue factor. The company is based in Miramar, FL. The company was founded by Hing C. Wong, Jon Weidanz, Peter R. Rhode. Sunol Molecular was acquired by Altor BioScience Corp., part of ImmunityBio, Inc. from August 01, 2017 on March 25, 2005.

Receptor Logic, Inc. provides a novel solution for the treatment of infectious diseases and cancers. The company was founded by Jon Weidanz in 2003 and is headquartered in Austin, TX.